NEUROCRINE BIOSCIENCES INC Increase (Decrease) in Accounts Receivable and Other Operating Assets
NEUROCRINE BIOSCIENCES INC (NBIX) reported Increase (Decrease) in Accounts Receivable and Other Operating Assets of $779.00 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets · last filed 2017-05-09
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable and other operating assets for the quarter ending 2017-03-31 was $779.00K, a 94.66% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable and other operating assets for the quarter ending 2016-03-31 was $14.58M, a 52.29% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable and other operating assets for the quarter ending 2015-03-31 was $30.55M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable and other operating assets for the quarter ending 2014-12-31 was $200.00K, a 51.92% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable and other operating assets for fiscal 2016 was -$1.79M, a 466.26% decline from fiscal 2015.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable and other operating assets for fiscal 2015 was $489.00K, a 70.74% decline from fiscal 2014.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable and other operating assets for fiscal 2014 was $1.67M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable and other operating assets for fiscal 2013 was -$13.53M, a 205.05% decline from fiscal 2012.
| Period end | Increase (Decrease) in Accounts Receivable and Other Operating Assets 3 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 6 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 9 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 12 month |
|---|---|---|---|---|
| 2017-03-31 | $779.00K 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | -$1.79M 10-K · filed 2017-02-14 | |||
| 2016-03-31 | $14.58M 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $489.00K 10-K · filed 2017-02-14 | |||
| 2015-03-31 | $30.55M 10-Q · filed 2016-05-05 | $30.75M derived: sum of 2 quarters · filed 2017-02-14 | $32.03M derived: sum of 3 quarters · filed 2017-02-14 | $33.07M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $1.48M derived: sum of 2 quarters · filed 2017-02-14 | $2.52M derived: sum of 3 quarters · filed 2017-02-14 | $1.67M 10-K · filed 2017-02-14 |
| 2014-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $2.32M derived: sum of 2 quarters · filed 2014-11-04 | $1.47M 10-Q · filed 2014-11-04 | $1.89M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | $196.00K 10-Q · filed 2014-08-06 | $612.00K derived: sum of 3 quarters · filed 2016-02-11 | $762.00K derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | -$850.00K 10-Q · filed 2015-04-30 | -$434.00K derived: sum of 2 quarters · filed 2016-02-11 | -$284.00K derived: sum of 3 quarters · filed 2016-02-11 | -$288.00K derived: sum of 4 quarters · filed 2016-02-11 |
| 2013-12-31 | $416.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $566.00K derived: sum of 2 quarters · filed 2016-02-11 | $562.00K derived: sum of 3 quarters · filed 2016-02-11 | -$13.53M 10-K · filed 2016-02-11 |
| 2013-09-30 | $150.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $146.00K derived: sum of 2 quarters · filed 2014-11-04 | -$13.94M 10-Q · filed 2014-11-04 | -$1.75M derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | -$14.09M 10-Q · filed 2014-08-06 | -$1.90M derived: sum of 3 quarters · filed 2015-02-09 | -$1.56M derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-03-31 | -$14.09M 10-Q · filed 2014-05-01 | -$1.90M derived: sum of 2 quarters · filed 2015-02-09 | -$1.56M derived: sum of 3 quarters · filed 2015-02-09 | -$1.73M derived: sum of 4 quarters · filed 2015-02-09 |
| 2012-12-31 | $12.19M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-09 | $12.53M derived: sum of 2 quarters · filed 2015-02-09 | $12.36M derived: sum of 3 quarters · filed 2015-02-09 | $12.88M 10-K · filed 2015-02-09 |
| 2012-09-30 | $339.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $169.00K derived: sum of 2 quarters · filed 2013-10-29 | $684.00K 10-Q · filed 2013-10-29 | -$20.44M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | -$170.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | $345.00K 10-Q · filed 2013-07-26 | -$20.78M derived: sum of 3 quarters · filed 2014-02-11 | -$1.16M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $515.00K 10-Q · filed 2013-05-02 | -$20.61M derived: sum of 2 quarters · filed 2014-02-11 | -$990.00K derived: sum of 3 quarters · filed 2014-02-11 | -$1.06M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | -$21.12M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | -$1.50M derived: sum of 2 quarters · filed 2014-02-11 | -$1.57M derived: sum of 3 quarters · filed 2014-02-11 | -$2.81M 10-K · filed 2014-02-11 |
| 2011-09-30 | $19.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | $19.55M derived: sum of 2 quarters · filed 2012-10-31 | $18.31M 10-Q · filed 2012-10-31 | $17.87M derived: sum of 4 quarters · filed 2013-02-08 |
| 2011-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-31 | -$1.31M 10-Q · filed 2012-07-31 | -$1.74M derived: sum of 3 quarters · filed 2013-02-08 | $2.50M derived: sum of 4 quarters · filed 2013-02-08 |
| 2011-03-31 | -$1.24M 10-Q · filed 2012-05-02 | -$1.68M derived: sum of 2 quarters · filed 2013-02-08 | $2.57M derived: sum of 3 quarters · filed 2013-02-08 | |
| 2010-12-31 | -$435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $3.81M derived: sum of 2 quarters · filed 2013-02-08 | $4.28M 10-K · filed 2013-02-08 | |
| 2010-09-30 | $4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $4.71M 10-Q · filed 2011-10-31 | ||
| 2010-06-30 | $465.00K 10-Q · filed 2011-07-29 | |||
| 2009-12-31 | -$2.45M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |